Senseonics Reports Sustained Yearlong Real-World Performance for Eversense 365

Overview

• Senseonics presented company-sourced real-world data at ATTD from the first 5,059 Eversense 365 sensors used by U.S. adults on open-loop insulin regimens.
• Users recorded an average transmitter wear time of 93.8% with a mean GMI of 7.14% and mean Time in Range of 66%, and more than 75% met hypoglycemia targets.
• Adherence and glycemic outcomes were comparable between the first and second six-month periods, indicating consistent performance from a single implanted sensor over one year.
• Outcomes improved with age, including mean GMI 6.99, Time in Range above 70% and wear above 95% for those older than 65, while 18–25-year-olds averaged GMI 7.3 with wear over 90%.
• An early readout from roughly 120 users combining Eversense 365 with the twiist AID system showed GMI 6.79%, Time in Range 77% and 2.7% time in hypoglycemia, with findings labeled preliminary and longer-term analyses planned.